GlobeNewsWire
13 Jun 2026, 11:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Intellia's Phase 3 HAELO trial for lonvo-z showed an 87% reduction in mean monthly HAE attacks and 62% of patients remained entirely attack-free. — Strong clinical efficacy in a pivotal Phase 3 trial significantly increases the probability of regulatory approval and commercial success for a high-value gene editing therapy.
+0.80Intellia has initiated a rolling Biologics License Application (BLA) with the FDA and anticipates U.S. approval and launch in the first half of 2027. — The transition from clinical trials to the formal regulatory submission process provides a clear timeline for potential revenue generation.
+0.60Lonvo-z demonstrated a favorable safety profile with only mild to moderate adverse events and no serious adverse events observed in the treatment arm. — The absence of serious adverse events is critical for CRISPR-based therapies, as safety concerns are often the primary hurdle for FDA approval of gene editing.
+0.50Continue reading
6 related stories
Search tags
Which stocks this story touches
The company reported positive Phase 3 results for its gene-editing candidate lonvo-z and is proceeding toward FDA approval.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
16h ago
